Highlight
• Large-scale randomized trial evaluated the effect of blood-based multicancer early-detection testing on late-stage cancer diagnosis in adults aged 50 to 77.
• Primary endpoint showed no statistically significant reduction in stage III or IV cancers after three screening rounds.
• A key secondary endpoint suggested a potential reduction in stage IV cancer incidence with an incidence rate ratio of 0.86, approaching statistical significance.
• Multi-round testing was well-tolerated with less than 1% adverse events and no serious trial-related harms.
